National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 5250-5251 [2024-01571]
Download as PDF
<![CDATA[
5250
Federal Register / Vol. 89, No. 18 / Friday, January 26, 2024 / Notices
Date: March 13, 2024.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892.
Contact Person: Preethy Nayar, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Institute on Drug Abuse,
NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, 301–443–4577,
nayarp2@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: January 22, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–01568 Filed 1–25–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Human Genome Research
Institute; Notice of Closed Meetings
lotter on DSK11XQN23PROD with NOTICES1
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Human
Genome Research Institute Special Emphasis
Panel; Center for ELSI Resource and Analysis
(CERA).
Date: March 13, 2024.
Time: 2:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Rudy O. Pozzatti, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, MSC 6908, Bethesda, MD
20892, (301) 402–8739, pozzattr@
mail.nih.gov.
VerDate Sep<11>2014
18:02 Jan 25, 2024
Jkt 262001
Name of Committee: National Human
Genome Research Institute Special Emphasis
Panel; Data Integration and Statistical
Analysis Methods (DISAM).
Date: March 15, 2024.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Sarah Jo Wheelan, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Institute for Human
Genome Research, National Institutes of
Health, 6700B Rockledge Drive, MSC 6908,
Bethesda, MD 20892, (301) 402–8823,
wheelansj@nih.gov.
Name of Committee: National Human
Genome Research Institute Special Emphasis
Panel; Advancing Genomic Medicine
Research (AGMR).
Date: March 18, 2024.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Sarah Jo Wheelan, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Institute for Human
Genome Research, National Institutes of
Health, 6700B Rockledge Drive, MSC 6908,
Bethesda, MD 20892, (301) 402–8823,
wheelansj@nih.gov.
Name of Committee: National Human
Genome Research Institute Special Emphasis
Panel; Genomics & Health Equity.
Date: March 22, 2024.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Rudy O. Pozzatti, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, MSC 6908, Bethesda, MD
20892, (301) 402–0838, pozzattr@
mail.nih.gov.
Name of Committee: National Human
Genome Research Institute Special Emphasis
Panel; Diversity Action Plan (DAP).
Date: March 26, 2024.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Sarah Jo Wheelan, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Institute for Human
Genome Research, National Institutes of
Health, 6700B Rockledge Drive, MSC 6908,
Bethesda, MD 20892, (301) 402–8823,
wheelansj@nih.gov.
Name of Committee: National Human
Genome Research Institute Special Emphasis
Panel; Genomic and Data Science Education.
Date: March 28, 2024.
Time: 11:00 a.m. to 3:00 p.m.
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
Agenda: To review and evaluate grant
applications.
Place: National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Keith McKenney, Ph.D.,
Scientific Review Officer, National Human
Genome Research Institute, National
Institutes of Health, 6700B Rockledge Drive,
MSC 6908, Bethesda, MD 20892, (301) 717–
2348, mckenneyk@mail.nih.gov.
Name of Committee: National Human
Genome Research Institute Special Emphasis
Panel; Network of Genomics Enabled
Learning Health Systems.
Date: March 29, 2024.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Sarah Jo Wheelan, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Institute for Human
Genome Research, National Institutes of
Health, 6700B Rockledge Drive, MSC 6908,
Bethesda, MD 20892, (301) 402–8823,
wheelansj@nih.gov.
Name of Committee: National Human
Genome Research Institute Special Emphasis
Panel; Pangenome Informatics Tools.
Date: April 5, 2024.
Time: 12:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Keith McKenney, Ph.D.,
Scientific Review Officer, National Human
Genome Research Institute, National
Institutes of Health, 6700B Rockledge Drive,
MSC 6908, Bethesda, MD 20892, (301) 717–
2348, mckenneyk@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.172, Human Genome
Research, National Institutes of Health, HHS)
Dated: January 22, 2024.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–01523 Filed 1–25–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
E:\FR\FM\26JAN1.SGM
26JAN1
Federal Register / Vol. 89, No. 18 / Friday, January 26, 2024 / Notices
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; HHS–NIH–SBIR PHS 2024–
1 Phase I/II: Development of Next-Gen
Devices and Materials-Based Platforms for
the Admin of HIV–1 bNAbs (Topic 124); PHS
2020–1 Phase II: Particle-based Co-delivery of
HIV immunogens as Next-Gen vaccines
(Topic 77).
Date: February 22, 2024.
Time: 11:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G33,
Rockville, MD 20892 (Video Assisted
Meeting).
Contact Person: Poonam Pegu, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G33, Rockville, MD
20852, 240–292–0719, poonam.pegu@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: January 22, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–01571 Filed 1–25–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
lotter on DSK11XQN23PROD with NOTICES1
National Cancer Institute; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Frederick National
Laboratory Advisory Committee to the
National Cancer Institute, February 29,
2024, 1:00 p.m. to February 29, 2024,
4:00 p.m., National Cancer Institute—
Shady Grove, 9609 Medical Center
Drive, Rockville, MD 20850 which was
published in the Federal Register on
November 7, 2023, FR Doc 2023–24584,
88 FR 76837.
This meeting notice is being amended
to change the meeting date from
February 29, 2024 to March 11, 2024.
The meeting format, agenda and time
will stay the same. The meeting can be
VerDate Sep<11>2014
18:02 Jan 25, 2024
Jkt 262001
accessed from the NIH Videocast at the
following link: https://videocast.
nih.gov/. The meeting is open to the
public.
DEPARTMENT OF HOMELAND
SECURITY
Dated: January 23, 2024.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[OMB Control Number 1651–0136]
[FR Doc. 2024–01594 Filed 1–25–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Immune Mechanisms at the
Maternal-Fetal Interface (R01 Clinical Trial
Not Allowed).
Date: February 28–29, 2024.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G54,
Rockville, MD 20892 (Video Assisted
Meeting).
Contact Person: Hitendra S. Chand, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G54, Rockville, MD
20852, (240) 627–3245, hiten.chand@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: January 22, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–01570 Filed 1–25–24; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
5251
U.S. Customs and Border Protection
Agency Information Collection
Activities; Extension; Generic
Clearance for the Collection of
Qualitative Feedback on Agency
Service Delivery
U.S. Customs and Border
Protection (CBP), Department of
Homeland Security.
ACTION: 60-Day notice and request for
comments.
AGENCY:
The Department of Homeland
Security, U.S. Customs and Border
Protection (CBP) will be submitting the
following information collection request
to the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995 (PRA). The
information collection is published in
the Federal Register to obtain comments
from the public and affected agencies.
DATES: Comments are encouraged and
must be submitted (no later than March
26, 2024) to be assured of consideration.
ADDRESSES: Written comments and/or
suggestions regarding the item(s)
contained in this notice must include
the OMB Control Number 1651–0136 in
the subject line and the agency name.
Please use the following method to
submit comments:
Email. Submit comments to: CBP_
PRA@cbp.dhs.gov.
FOR FURTHER INFORMATION CONTACT:
Requests for additional PRA information
should be directed to Seth Renkema,
Chief, Economic Impact Analysis
Branch, U.S. Customs and Border
Protection, Office of Trade, Regulations
and Rulings, 90 K Street NE, 10th Floor,
Washington, DC 20229–1177,
Telephone number 202–325–0056 or via
email CBP_PRA@cbp.dhs.gov. Please
note that the contact information
provided here is solely for questions
regarding this notice. Individuals
seeking information about other CBP
programs should contact the CBP
National Customer Service Center at
877–227–5511, (TTY) 1–800–877–8339,
or CBP website at https://www.cbp.gov/.
SUPPLEMENTARY INFORMATION: CBP
invites the general public and other
Federal agencies to comment on the
proposed and/or continuing information
collections pursuant to the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501
et seq.). This process is conducted in
accordance with 5 CFR 1320.8. Written
comments and suggestions from the
SUMMARY:
E:\FR\FM\26JAN1.SGM
26JAN1
]]>Agencies
[Federal Register Volume 89, Number 18 (Friday, January 26, 2024)]
[Notices]
[Pages 5250-5251]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-01571]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C.,
[[Page 5251]]
as amended. The contract proposals and the discussions could disclose
confidential trade secrets or commercial property such as patentable
material, and personal information concerning individuals associated
with the contract proposals, the disclosure of which would constitute a
clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; HHS-NIH-SBIR PHS 2024-1 Phase I/II:
Development of Next-Gen Devices and Materials-Based Platforms for
the Admin of HIV-1 bNAbs (Topic 124); PHS 2020-1 Phase II: Particle-
based Co-delivery of HIV immunogens as Next-Gen vaccines (Topic 77).
Date: February 22, 2024.
Time: 11:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3G33,
Rockville, MD 20892 (Video Assisted Meeting).
Contact Person: Poonam Pegu, Ph.D., Scientific Review Officer,
Scientific Review Program, Division of Extramural Activities,
National Institute of Allergy and Infectious Diseases, National
Institutes of Health, 5601 Fishers Lane, Room 3G33, Rockville, MD
20852, 240-292-0719, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: January 22, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-01571 Filed 1-25-24; 8:45 am]
BILLING CODE 4140-01-P
